TuisAZN • NASDAQ
add
AstraZeneca PLC
Vorige sluiting
$66,58
Dagwisseling
$66,85 - $67,57
Jaarwisseling
$60,48 - $87,67
Markkapitalisasie
210,98Â mjd USD
Gemiddelde volume
4,98Â m
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 13,56Â mjd | 18,04% |
Bedryfskoste | 7,79Â mjd | 4,64% |
Netto inkomste | 1,43Â mjd | 4,00% |
Netto winsgrens | 10,53 | -11,96% |
Wins per aandeel | 2,08 | 140,46% |
EBITDA | 4,63Â mjd | 45,69% |
Effektiewe belastingkoers | 21,61% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 4,93Â mjd | -3,62% |
Totale bates | 104,92Â mjd | 9,20% |
Totale aanspreeklikheid | 64,12Â mjd | 8,92% |
Totale ekwiteit | 40,80 mjd | — |
Uitstaande aandele | 1,55 mjd | — |
Prys om te bespreek | 2,53 | — |
Opbrengs op bates | 7,92% | — |
Opbrengs op kapitaal | 11,38% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 1,43Â mjd | 4,00% |
Kontant van bedrywe | 3,38Â mjd | 8,64% |
Kontant van beleggings | -1,51Â mjd | -24,00% |
Kontant van finansiering | -4,13Â mjd | -51,54% |
Netto kontantverandering | -2,24Â mjd | -163,15% |
Beskikbare kontantvloei | 2,05Â mjd | -12,38% |
Meer oor
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, United Kingdom; Gothenburg, Sweden and Gaithersburg in Maryland, U.S.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Wikipedia
Gestig
06 Apr. 1999
Hoofkwartier
Webwerf
Werknemers
89Â 900